The contract manufacturing market for live biotherapeutics and microbiome products:By RootsAnalysis:
Manufacturing live biotherapeutic product is both technically challenging and financially demanding; as a result, innovator firms are becoming increasingly reliant on contract service providers to access specialized facilities and optimize overall costs.
Roots Analysis is pleased to announce the publication of its recent study, titled, “Live Biotherapeutic Products and Microbiome Contract Manufacturing Market, 2020-2030: Focus on Active Pharmaceutical Ingredients and Finished Dosage Forms, 2020-2030.”
The report features an extensive study of the current landscape and future opportunities related to contract services for microbiome therapeutics. The study features an in-depth analysis, highlighting the capabilities of a diverse set of contract service providers, including CMOs and CDMOs. Amongst other elements, the report includes:
A detailed review of the overall landscape of companies offering contract services for manufacturing of microbiome therapeutics.
A list of companies with in-house manufacturing facilities for microbiome therapeutics.
Elaborate profiles of key industry players (large and mid-sized companies, established before 2000) based in North America, Europe and Asia-Pacific.
An assessment of microbiome contract manufacturing capability in different regions.
A list of nearly 50 microbiome-focused drug developers that are anticipated to partner with contract manufacturers.
A detailed clinical trial analysis of more than 150 completed, ongoing and planned studies of various microbiome therapeutics sponsored by both industry and non-industry players.
An estimate of the overall, installed capacity for manufacturing of microbiome therapeutics, taking into consideration the capabilities of various stakeholders.
Roots Analysis Private Limited
+1 (415) 800 3415